Status:
COMPLETED
Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at...
Eligibility Criteria
Inclusion
- Have a pathologically confirmed diagnosis of a solid tumor malignancy that is refractory to conventional therapy or for which no therapy exists. Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- Be greater than or equal to 18 years old.
- Must not be eligible for therapy of higher curative potential. (NB: Where an alternative therapy has been shown to prolong survival in an analogous population, that therapy will be offered to the patient prior to discussing this study.)
- Have a Karnofsky Performance Status (KPS) of greater than or equal to 70.
- Have an estimated life expectancy of greater than or equal to 12 weeks.
- Be male or a non-pregnant, non-lactating female. Patients who are fertile must agree to use an effective barrier method of birth control (ie, latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy.
- Have a negative serum or urine pregnancy test within 10 days of study treatment (if patient is a female of childbearing potential).
- Sign a written informed consent form.
- Have adequate organ function as indicated by the following laboratory values, obtained within 2 weeks prior to registration: A. ANC: greater than or equal to 1.5 × 10 \^9th/L; B. Platelets: greater than or equal to 100 × 10 \^9th/L; C.Serum bilirubin: less than 2.0 mg/dL; D. AST and ALT: less than 3 x ULN\* without liver involvement OR less than 5 x ULN with liver involvement; E. Serum creatinine: less than or equal to 2.0 mg/dL. NOTE: ULN = Institutional Upper Limit of Normal.
Exclusion
- Have received previous treatment with clofarabine.
- Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
- Are pregnant or lactating.
- Have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.
- Have received any chemotherapy, major surgery, or irradiation, whether conventional or investigational, 28 days before treatment in this study (42 days for mitomycin-C or nitrosourea).
- Have not recovered from acute toxicities of all previous therapy prior to enrollment.
- Have any other severe concurrent disease, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study (eg, uncontrolled severe insulin-dependent diabetes, uncontrolled hypertension, transient ischemic attacks, uncontrolled symptomatic coronary artery disease, etc). Patients with abnormal cardiac function who are in consideration for study participation should be discussed with the Medical Monitor prior to enrollment.
- Have received prior radiation therapy to greater than or equal to 25% of the bone marrow (eg, no whole pelvic irradiation is allowed) and have not recovered from the acute side effects of radiotherapy.
- Have symptomatic or untreated central nervous system (CNS) metastases.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00125827
Start Date
October 1 2003
End Date
February 1 2006
Last Update
March 19 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Mary Crowley Medical Research Center
Dallas, Texas, United States, 75246
2
Tyler Cancer Institute
Tyler, Texas, United States, 75702
3
Cancer Care Northwest
Spokane, Washington, United States, 99218